Radiotherapy Versus Chemotherapy plus Radiotherapy in Surgically Treated IIIA N2 Non–Small-Cell Lung Cancer (original) (raw)

Abstract

Preoperative chemotherapy in patients with stage III non-small-cell lung cancer (NSCLC) remains controversial. Phase II trials utilizing preoperative chemotherapy in selected patients have achieved complete resection rates of 50%-70% with 3-5 year failure-free survival rates of 15%-33%. Between October 1992 and November 1994, 57 adults (50 of whom were evaluable) with surgically staged IIIA NSCLC and pathologically documented ipsilateral mediastinal nodal involvement (N2) were enrolled in a Cancer and Leukemia Group B randomized trial. Preoperative therapy was thought to be critical to facilitating surgical resectability. For patients randomized to the radiotherapy/surgery/radiotherapy (RSR) arm (n = 24), treatment consisted of preoperative radiation therapy (RT) at 40 Gy, surgery, and then additional RT at 14-20 Gy. For patients randomized to the chemotherapy/surgery/chemotherapy/radiotherapy (CSCR) arm (n = 26), treatment consisted of 2 cycles of cisplatin/etoposide with filgrastim support (PE) followed by surgery, 2 more cycles of PE, then RT 54-60 Gy. The total dose of RT on either arm was 54 Gy if completely resected or 60 Gy if incompletely resected or unresected. Clinical characteristics were well balanced between the two arms. Thoracotomy was performed in 42 patients (84%), 28 (67%) of whom had complete resection. The median failure-free and overall survival rates were 12 months (95% confidence interval [CI], 9-23 months) and 23 months (95% CI, 19 months-∞) for the RSR arm and 11 months (95% CI, 5-20 months) and 18 months (95% CI, 12-32 months) for the CSCR arm. The rates of overall and complete surgical resection, downstaging of nodal involvement, and failure-free (P = 0.92) and overall survival (P = 0.41) did not differ between the two treatment arms. Moreover, in this trial, the chemotherapy regimen was sufficiently toxic to have had a lower completion rate of prescribed therapy in the CSCR arm than in the RSR arm.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (39)

  1. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47.
  2. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89:225S-233S.
  3. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemother- apy plus high-dose radiation versus radiation alone in stage III non-small-cell lung can- cer. N Engl J Med 1990; 323:940-945.
  4. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small- cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88:1210-1215.
  5. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analy- sis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83:417-423.
  6. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cis- platin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326:524-530.
  7. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88- 08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87:198-205.
  8. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiother- Anthony D. Elias et al apy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 1996; 125:723-729.
  9. Skarin A, Jochelson M, Sheldon T, et al. Neoadjuvant chemotherapy in marginally re- sectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol 1989; 40:266-274.
  10. Strauss GM, Langer MP, Elias AD, et al. Multimodality treatment of stage IIIA non- small-cell lung carcinoma: a critical review of the literature and strategies for future re- search. J Clin Oncol 1992; 10:829-838.
  11. Sugarbaker DJ, Kirn DH, Mentzer SJ, et al. Neoadjuvant chemotherapy downstages pa- tients with stage IIIA non-small cell lung cancer (NSCLC): Amer Coll Surgeons, 1992.
  12. Luikart SD, Goutsou M, Mitchell ED, et al. Phase I/II trial of etoposide and carbo- platin in extensive small-cell lung cancer. A report from the Cancer and Leukemia Group B. Am J Clin Oncol 1993; 16:127-131.
  13. Rusch VW, Albain KS, Crowley JJ, et al. Neoadjuvant therapy: a novel and effective treatment for stage IIIB non-small cell lung cancer. Southwest Oncology Group. Ann Thorac Surg 1994; 58:290-294; discussion 294-295.
  14. George SL, Desu MM. Planning the size and duration of a clinical trial studying the time to some critical event. J Chronic Dis 1974; 27:15-24.
  15. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-556.
  16. Kaplan E, Meier R. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53:457-481.
  17. Cox D. Analysis of binary data. London: Chapman and Hall, 1970.
  18. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86:673-680.
  19. Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21:1-6.
  20. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung can- cer. N Engl J Med 1994; 330:153-158.
  21. Wagner H, Jr., Lad T, Piantadosi S, et al. Randomized phase II evaluation of preopera- tive radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell can- cer of the lung. LCSG 881. Chest 1994; 106:348S-354S.
  22. Dautzenberg B, Benichou J, Allard P, et al. Failure of the perioperative PCV neoadju- vant polychemotherapy in resectable bronchogenic non-small cell carcinoma. Results from a randomized phase II trial. Cancer 1990; 65:2435-2441.
  23. Pass HI, Pogrebniak HW, Steinberg SM, et al. Randomized trial of neoadjuvant thera- py for lung cancer: interim analysis. Ann Thorac Surg 1992; 53:992-998.
  24. Elias AD, Skarin AT, Gonin R, et al. Neoadjuvant treatment of stage IIIA non-small cell lung cancer. Long-term results. Am J Clin Oncol 1994; 17:26-36.
  25. Coleman CN, Mitchell JB. Clinical radiosensitization: why it does and does not work. J Clin Oncol 1999; 17:1-3.
  26. Pisters KM, Kris MG, Gralla RJ, et al. Pathologic complete response in advanced non- small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol 1993; 11:1757-1762.
  27. Faber LP, Kittle CF, Warren WH, et al. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg 1989; 47:669-675; discussion 676-667.
  28. Burkes RL, Ginsberg RJ, Shepherd FA, et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial. J Clin Oncol 1992; 10:580-586.
  29. Strauss GM, Herndon JE, Sherman DD, et al. Neoadjuvant chemotherapy and radio- therapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992; 10:1237-1244.
  30. Reddy S, Faber LP, Baumann LA, et al. Preoperative radiation therapy in regionally lo- calized stage III non-small cell lung carcinoma: long-term results and patterns of fail- ure. Int J Radiat Oncol Biol Phys 1990; 19:287-292.
  31. Elias AD, Skarin AT, Leong T, et al. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer 1997; 17:147-161.
  32. Bromley L, Szur L. Combined radiotherapy and resection for carcinoma of the bronchus. Lancet 1955.
  33. Shields TW, Higgins GA, Jr., Lawton R, et al. Preoperative x-ray therapy as an adjuvant in the treatment of bronchogenic carcinoma. J Thorac Cardiovasc Surg 1970; 59:49-61.
  34. Kirn DH, Lynch TJ, Mentzer SJ, et al. Multimodality therapy of patients with stage IIIA, N2 non-small-cell lung cancer. Impact of preoperative chemotherapy on re- sectability and downstaging. J Thorac Cardiovasc Surg 1993; 106:696-702.
  35. Bueno R, Richards WG, Swanson SJ, et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000; 70:1826-1831.
  36. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest ra- diotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung can- cer: mature results of Southwest Oncology Group phase II study 88-05. J Clin Oncol 1995; 13:1880-1892.
  37. Pantel K, Izbicki JR, Angstwurm M, et al. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res 1993; 53:1027-1031.
  38. Pantel K, Izbicki J, Passlick B, et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 1996; 347:649-653.
  39. Cote RJ, Beattie EJ, Chaiwun B, et al. Detection of occult bone marrow micrometas- tases in patients with operable lung carcinoma. Ann Surg 1995; 222:415-423; discus- sion 423-415.